Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2016 - 20193

Settings

Author: search.filters.author.Onal, CemSubject: search.filters.subject.Prostate

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Metachronous Prostate Metastasis of Renal Cell Carcinoma: Case Report and Review of the Literature
    (2016) Guler, Ozan Cem; Bal, Nebil; Onal, Cem; https://orcid.org/0000-0001-6908-3412; https://orcid.org/0000-0002-2742-9021; 26739102; AAC-5654-2020; HOC-5611-2023
    Secondary tumors of the prostate are very rare, and only a few reports of prostate metastasis originating from renal cell carcinoma (RCC) have been published. The reported 5-year survival rate has been approximately 35% for patients who underwent nephrectomy and surgical resection of a solitary metastasis. Immunohistochemical analysis showed that CD10 and vimentin positivity were helpful for distinguishing clear cell RCC from other renal tumors. We report a case with delayed metachronous metastasis of RCC to the prostate, which clinically mimicked benign prostatic hyperplasia or prostate cancer, treated with transurethral resection and palliative radiotherapy. (C) 2016 Elsevier Inc. All rights reserved.
  • No Thumbnail Available
    Item
    Dosimetric Analysis of Testicular Doses in Prostate Intensity-Modulated and Volumetric-Modulated Arc Radiation Therapy at Different Energy Levels
    (2016) Onal, Cem; ArsIan, Gungor; Dolek, Yemliha; Efe, Esma; 0000-0002-2742-9021; 27623736; D-5195-2014
    The aim of this study is to evaluate the incidental testicular doses during prostate radiation therapy with intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc radiotherapy (VMAT) at different energies. Dosimetric data of 15 patients with intermediate-risk prostate cancer who were treated with radiotherapy were analyzed. The prescribed dose was 78 Gy in 39 fractions. Dosimetric analysis compared testicular doses generated by 7-field intensity-modulated radiotherapy and volumetric modulated arc radiotherapy with a single arc at 6, 10, and 15 MV energy levels. Testicular doses calculated from the treatment planning system and doses measured from the detectors were analyzed. Mean testicular doses from the intensity-modulated radiotherapy and volumetric-modulated arc radiotherapy per fraction calculated in the treatment planning system were 16.3 +/- 10.3 cGy vs 21.5 +/- 11.2 cGy (p = 0.03) at 6 MV, 13.4 +/- 10.4 cGy vs 17.8 +/- 10.7 cGy (p = 0.04) at 10 MV, and 10.6 +/- 8.5 cGy vs 14.5 +/- 8.6 cGy (p = 0.03) at 15 MV, respectively. Mean scattered testicular doses in the phantom measurements were 99.5 +/- 17.2 cGy, 118.7 +/- 16.4 cGy, and 193.9 +/- 14.5 cGy at 6, 10, and 15 MV, respectively, in the intensity-modulated radiotherapy plans. In the volumetric-modulated arc radiotherapy plans, corresponding testicular doses per course were 90.4 +/- 16.3 cGy, 103.6 +/- 16.4 cGy, and 139.3 +/- 14.6 cGy at 6, 10, and 15 MV, respectively. In conclusions, this study was the first to measure the incidental testicular doses by intensity-modulated radiotherapy and volumetric-modulated arc radiotherapy plans at different energy levels during prostate-only irradiation. Higher photon energy and volumetric-modulated arc radiotherapy plans resulted in higher incidental testicular doses compared with lower photon energy and intensity-modulated radiotherapy plans. (C) 2016 American Association of Medical Dosimetrists.
  • No Thumbnail Available
    Item
    Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate
    (2019) Yildirim, Berna Akkus; Onal, Cem; Kose, Fatih; Oymak, Ezgi; Sedef, Ali Murat; Besen, Ali Ayberk; Aksoy, Sercan; Guler, Ozan Cem; Sumbul, Ahmet Taner; Mualloglu, Sadik; Mertsoylu, Huseyin; Ozyigit, Gokhan; 30701292
    Purpose To evaluate the potential benefit of curative radiotherapy (RT) to the primary tumor in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone. Materials and methods The clinical parameters of 106 mCRPC patients treated with abiraterone were retrospectively evaluated. Patients were either oligometastatic (<= 5 metastases) at diagnosis or became oligometastatic after the systemic treatment was analyzed. Local RT to the primary tumor and pelvic lymphatics was delivered in 44 patients (41%), and 62 patients (59%) did not have RT to the primary tumor. After propensity match analysis, a total of 92 patients were analyzed. Resultsn Median follow-up time was 14.2 months (range: 2.3-54.9 months). Median overall survival (OS) was higher in patients treated with local RT to the primary tumor than in those treated without local RT with borderline significance (24.1 vs. 21.4 months; p=0.08). Local RT to the prostate and pelvic lymphatics significantly diminished the local recurrence rate (16 patients, 31% vs. 2 patients, 5%; p=0.003). In multivariate analysis, the prostate specific antigen (PSA) response >= 50% of the baseline obtained 3 weeks after abiraterone therapy was the only significant prognostic factor for better OS and progression-free survival (PFS). Patients treated with primary RT to the prostate had significantly less progression under abiraterone and a longer abiraterone period than those treated without local prostate RT. Conclusions Local prostate RT significantly improved OS and local control in mCRPC patients treated with abiraterone. The patients treated with primary RT had significantly less progression under abiraterone and a longer abiraterone period than those treated without local prostate RT.